Antibody Engineering and Therapeutics Europe

Andrew Bradbury, Chief Scientific Officer of Specifica Biosciences, a Q2 Solutions company, will be presenting on Antibody and VHH Discovery & Optimization for Affinity, Potency & Developability, on Tuesday, June 6 at 14:35-15:05 local time.

Developing VHH for clinical use involves many engineering steps after camelid immunization. These include humanization, affinity maturation, removal of liabilities, and engineering Protein A binding. Improving one characteristic often impairs another. We designed and built a VHH library based on the Generation 3 concept that enables bypassing many of these processes: human HCDR1-2 purged of sequence liabilities are inserted into clinical VHH scaffolds and filtered for Protein A binding. When combined with >1e8 human HCDR3s, the resultant library is able to yield VHH with drug-like characteristics.

June 6, 2023 – June 8, 2023 | Amsterdam – Netherlands